135 related articles for article (PubMed ID: 30825971)
1. Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results.
Lambrecht M; Clementel E; Sonke JJ; Nestle U; Adebahr S; Guckenberger M; Andratschke N; Weber DC; Verheij M; Hurkmans CW
Radiother Oncol; 2019 Mar; 132():63-69. PubMed ID: 30825971
[TBL] [Abstract][Full Text] [Related]
2. Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.
Lambrecht M; Melidis C; Sonke JJ; Adebahr S; Boellaard R; Verheij M; Guckenberger M; Nestle U; Hurkmans C
Radiat Oncol; 2016 Jan; 11():7. PubMed ID: 26791788
[TBL] [Abstract][Full Text] [Related]
3. Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.
Moustakis C; Blanck O; Ebrahimi Tazehmahalleh F; Ka Heng Chan M; Ernst I; Krieger T; Duma MN; Oechsner M; Ganswindt U; Heinz C; Alheit H; Blank H; Nestle U; Wiehle R; Kornhuber C; Ostheimer C; Petersen C; Pollul G; Baus W; Altenstein G; Beckers E; Jurianz K; Sterzing F; Kretschmer M; Seegenschmiedt H; Maass T; Droege S; Wolf U; Schoeffler J; Haverkamp U; Eich HT; Guckenberger M
Strahlenther Onkol; 2017 Oct; 193(10):780-790. PubMed ID: 28567503
[TBL] [Abstract][Full Text] [Related]
4. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
Hoffmann L; Persson GF; Nygård L; Nielsen TB; Borrisova S; Gaard-Petersen F; Josipovic M; Khalil AA; Kjeldsen R; Knap MM; Kristiansen C; Møller DS; Ottosson W; Sand H; Thing R; Pøhl M; Schytte T
Radiother Oncol; 2022 Jun; 171():53-61. PubMed ID: 35421513
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases.
Chi A; Jang SY; Welsh JS; Nguyen NP; Ong E; Gobar L; Komaki R
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):856-62. PubMed ID: 21255942
[TBL] [Abstract][Full Text] [Related]
7. Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure.
Stelmes JJ; Vu E; Grégoire V; Simon C; Clementel E; Kazmierska J; Grant W; Ozsahin M; Tomsej M; Vieillevigne L; Fortpied C; Hurkmans EC; Branquinho A; Andratschke N; Zimmermann F; Weber DC
Radiat Oncol; 2021 May; 16(1):81. PubMed ID: 33933118
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of plan quality and treatment efficiency for single-isocenter/two-lesion lung stereotactic body radiation therapy.
Sanford L; Molloy J; Kumar S; Randall M; McGarry R; Pokhrel D
J Appl Clin Med Phys; 2019 Jan; 20(1):118-127. PubMed ID: 30548205
[TBL] [Abstract][Full Text] [Related]
9. The TRENDY multi-center randomized trial on hepatocellular carcinoma - Trial QA including automated treatment planning and benchmark-case results.
Habraken SJM; Sharfo AWM; Buijsen J; Verbakel WFAR; Haasbeek CJA; Öllers MC; Westerveld H; van Wieringen N; Reerink O; Seravalli E; Braam PM; Wendling M; Lacornerie T; Mirabel X; Weytjens R; Depuydt L; Tanadini-Lang S; Riesterer O; Haustermans K; Depuydt T; Dwarkasing RS; Willemssen FEJA; Heijmen BJM; Méndez Romero A
Radiother Oncol; 2017 Dec; 125(3):507-513. PubMed ID: 29050954
[TBL] [Abstract][Full Text] [Related]
10. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
Christiaens M; Collette S; Overgaard J; Gregoire V; Kazmierska J; Castadot P; Giralt J; Grant W; Tomsej M; Bar-Deroma R; Monti AF; Hurkmans CW; Weber DC
Radiother Oncol; 2017 Jun; 123(3):424-430. PubMed ID: 28478912
[TBL] [Abstract][Full Text] [Related]
11. A multi-institutional study to assess adherence to lung stereotactic body radiotherapy planning goals.
Woerner A; Roeske JC; Harkenrider MM; Fan J; Aydogan B; Koshy M; Laureckas R; Vali F; Campana M; Surucu M
Med Phys; 2015 Aug; 42(8):4629-35. PubMed ID: 26233190
[TBL] [Abstract][Full Text] [Related]
12. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases.
Al-Hallaq HA; Chmura SJ; Salama JK; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Robinson CG; Pisansky TM; Winter KA; White JR; Xiao Y; Matuszak MM
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):155-163. PubMed ID: 27843033
[TBL] [Abstract][Full Text] [Related]
13. The impact of peer review of volume delineation in stereotactic body radiation therapy planning for primary lung cancer: a multicenter quality assurance study.
Lo AC; Liu M; Chan E; Lund C; Truong PT; Loewen S; Cao J; Schellenberg D; Carolan H; Berrang T; Wu J; Berthelet E; Olson R
J Thorac Oncol; 2014 Apr; 9(4):527-33. PubMed ID: 24736076
[TBL] [Abstract][Full Text] [Related]
14. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.
Adebahr S; Collette S; Shash E; Lambrecht M; Le Pechoux C; Faivre-Finn C; De Ruysscher D; Peulen H; Belderbos J; Dziadziuszko R; Fink C; Guckenberger M; Hurkmans C; Nestle U
Br J Radiol; 2015 Jul; 88(1051):20150036. PubMed ID: 25873481
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
16. Potential reduction of lung dose via VMAT with jaw tracking in the treatment of single-isocenter/two-lesion lung SBRT.
Pokhrel D; Sanford L; Halfman M; Molloy J
J Appl Clin Med Phys; 2019 May; 20(5):55-63. PubMed ID: 30955251
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced brachial plexus toxicity after SBRT of apically located lung lesions.
Lindberg K; Grozman V; Lindberg S; Onjukka E; Lax I; Lewensohn R; Wersäll P
Acta Oncol; 2019 Aug; 58(8):1178-1186. PubMed ID: 31066326
[No Abstract] [Full Text] [Related]
18. A comprehensive dosimetric study on switching from a Type-B to a Type-C dose algorithm for modern lung SBRT.
Zhou C; Bennion N; Ma R; Liang X; Wang S; Zvolanek K; Hyun M; Li X; Zhou S; Zhen W; Lin C; Wahl A; Zheng D
Radiat Oncol; 2017 May; 12(1):80. PubMed ID: 28476138
[TBL] [Abstract][Full Text] [Related]
19. The dosimetric effect of electron density overrides in 3DCRT Lung SBRT for a range of lung tumor dimensions.
Healy GEA; Marsh SH; Cousins AT
J Appl Clin Med Phys; 2018 Nov; 19(6):79-87. PubMed ID: 30199127
[TBL] [Abstract][Full Text] [Related]
20. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
